CN107184565A - A kind of preparation method of ibuprofen sustained release capsules - Google Patents
A kind of preparation method of ibuprofen sustained release capsules Download PDFInfo
- Publication number
- CN107184565A CN107184565A CN201710403211.3A CN201710403211A CN107184565A CN 107184565 A CN107184565 A CN 107184565A CN 201710403211 A CN201710403211 A CN 201710403211A CN 107184565 A CN107184565 A CN 107184565A
- Authority
- CN
- China
- Prior art keywords
- brufen
- preparation
- sba
- particle
- mesoporous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the preparation method of ibuprofen sustained release capsules, belong to field of pharmaceutical preparations.It comprises the following steps：1) mesoporous material and polyethylene glycol are added and ultrasound is carried out in solvent；2) brufen is added into dicyandiamide solution, stirring solvent flashing obtains the mesoporous particles of load brufen；Mesoporous particles are coated using organic polymer auxiliary material, the particle of acquisition pulverizes and sieves, encapsulated to produce.
Description
Technical field
The present invention relates to the preparation method of ibuprofen sustained release capsules, belong to field of pharmaceutical preparations.
Background technology
Brufen (brufen, ibuprofen) is a kind of NSAIDs (NSAIDS), with analgesia, anti-inflammatory,
Antirheumatic, antipyretic effect, it is slight to moderate pain such as arthralgia, courbature, neuralgia, headache, antimigraine, tooth for alleviating
Bitterly, dysmenorrhoea etc., is also used for generating heat caused by common cold or influenza.
Although having used more than 40 years in the mankind, brufen is considered as safe, as NSAIDs,
It still can cause numerous adverse reactions, including：1) digestive tract damage, with gastrointestinal reaction such as Nausea and vomiting, stomachache, stomach
Burn feeling and slight indigestion are the most common, and severe patient may occur in which gastric and duodenal ulcer, rotten to the corn and gastric perforation and go out
Blood；2) renal damage, be mainly shown as acute renal insufficiency, interstitial nephritis, town dolorosa nephritis, necrosis of renal papillae, albuminuria,
Nephrotic syndrome or renal failure etc.；3) hepatic lesion, almost all of NSAIDS results in hepatic lesion, shows as liver enzyme liter
Height, severe patient necrosis of liver cells；4) cutaneous anaphylaxis, such as fash, nettle rash, itch, exfoliative dermatitis, bullous skin disease
Etc. cutaneous anaphylaxis；5) hematopoietic disorders, such as anaemia, leukopenia, thrombopenia, pancytopenia, grain
Granulocytopenia etc.；And 6) neurological symptom, such as headache, drowsiness, dizzy, tinnitus.Wherein with gastrointestinal side effect
To be most common, it was reported that gastrointestinal side effect occurs in about 15%-30% long-term prescription person, or even there is digestibility and burst
Ulcer, severe patient can be with bleeding or perforation.Therefore, in order to improve its bioavilability, the times for spraying and pair for reducing patient are anti-
Should, improve its compliance, research brufen sustained-release preparation turn into clinical treatment in the urgent need to.
At present, brufen sustained-release preparation is mainly matrix type, the hydrophilic gel being prepared into using high-molecular organic material
Type or microsphere sustained-release preparation, however, some high-molecular organic materials when as drug delivery system there is also some defects, such as
Mechanical strength is low, poor chemical stability, biocompatibility are undesirable, or even has certain toxicity, limits it in vivo
Application.
In contrast to this, the silica (SiO of ordered mesoporous material such as nanostructured2) as drug carrier material there is nothing
Poison, preferably biocompatibility, chemistry and mechanical stability, hydrophilic and porous etc. property, can control adsorbed or wrap in theory
The diffusion rate of medicine is buried, and is not swelled under pH value change, does not also change porous, is also less prone to by microorganism attack,
So causing the extensive concern of people.Meanwhile, single SiO2Material is difficult to as drug controlled release system there are still some
The difficulty of solution.First, earth silicon material drug loading is relatively low, can significantly improve production cost；Second, silica material
Expect that rate of release is very fast after carrying medicament, is unable to reach sustained release purpose sometimes；3rd, earth silicon material is mainly in this area
Simple carrying medicament, can cause medicine stability to reduce on the premise of without any auxiliary material.
The content of the invention
The first aspect of the present invention is to provide a kind of preparation method of ibuprofen sustained release capsules, and it comprises the following steps：
1) mesoporous material and polyethylene glycol are added and ultrasound is carried out in solvent；
2) brufen is added into dicyandiamide solution, stirring solvent flashing obtains the mesoporous particles of load brufen；
3) mesoporous particles are coated using organic polymer auxiliary material, the particle of acquisition pulverizes and sieves, encapsulated to produce.
In one embodiment, the mesoporous material is selected from mesoporous silica particles and open-cell polypropylene particle foams
One or both of.
In still another embodiment, the mesoporous silica particles are selected from MCM-41, SBA-15, HMS, MSU, SBA-
3rd, the one or more in MCM-48 and TUD-1；Preferably SBA-15, the SBA-15 particle diameter are 1-2 μm, and average pore size is
8-11nm, specific surface area 600m2/g。
In another embodiment, the particle diameter of the open-cell polypropylene particle foams is 250-350 μm, and average pore size is
5-20 μm, percent opening is 70%.
In a preferred embodiment, the one kind or many of the solvent in methanol, ethanol, acetone and dichloromethane
Kind.
In still another embodiment, the weight ratio of the brufen, mesoporous material and polyethylene glycol is 1：0.5-5：
0.1-0.5.Further, the mesoporous material is made up of mesoporous silica particles and polypropylene porous particle, described mesoporous
The weight ratio of silica dioxide granule and polypropylene porous particle is 1：0.2-2；Further, the brufen, mesoporous dioxy
The weight ratio of silicon carbide particle, open-cell polypropylene particle foams and polyethylene glycol is 1：0.5：0.4：0.3.
It is preferably carried out at one in scheme, in step 1) in, methyl hexadecanoate, the cloth are also added into the solvent
The weight ratio of ibuprofen and methyl hexadecanoate is 1：0.05.
In another embodiment, the organic polymer auxiliary material is hydroxypropyl methylcellulose, methylcellulose, ethyl fibre
Tie up element, acrylic resin I-IV, hydroxypropyl cellulose, hypromellose phthalate, phthalic acid acetic acid fibre
One or more in dimension element and styrol maleic acid copolymers.
In one specifically embodiment, the preparation method of the ibuprofen sustained release capsules is as follows：
1) by SBA-15 and polyethylene glycol by weight 0.5：0.2 adds ultrasound 10-15min in ethanol；
2) brufen is added into dicyandiamide solution, wherein, brufen and SBA-15 weight ratio are 1：1, stirring volatilization is molten
Agent obtains the SBA-15 particles of load brufen；
3) hypromellose phthalate is dissolved in methanol-acetone solution (volume ratio 1：1) in, then to solution
The middle SBA-15 particles for adding load brufen, SBA-15 particles and the hydroxypropyl methylcellulose O-phthalic of the load brufen
The weight ratio of acid esters is 2：1, solvent flashing is stirred, the particle of acquisition crushes sieving for standby；
4) by open-cell polypropylene particle foams and polyethylene glycol by weight 0.4：0.1 adds ultrasound 15- in ethanol
20min；
5) brufen is added into dicyandiamide solution, wherein, the weight ratio of brufen and open-cell polypropylene particle foams is
0.5：0.4, stirring solvent flashing obtains the open-cell polypropylene particle foams of load brufen；
6) IV acrylic resins are dissolved in ethanol, the perforate polypropylene bubble of load brufen is then added into solution
Foam particle, the open-cell polypropylene particle foams of the load brufen are 3 with the weight ratio of IV acrylic resins：1, stirring is waved
Solvent is sent out, the particle of acquisition pulverizes and sieves, the particle obtained with step 3 loads capsule after being well mixed and produced.
The second aspect of the present invention is to provide ibuprofen sustained release capsules prepared by a kind of above method.
The third aspect of the present invention is to provide the ibuprofen sustained release capsules in terms for the treatment of inflammation or pain disease is prepared
Application in medicine.
Present invention discover that during mesoporous material load brufen, can after addition polyethylene glycol and methyl hexadecanoate
To improve load capacity of the mesoporous material to brufen, and on the premise of high capacity amount, it can also be ensured that load brufen is situated between
The sustained release rate of Porous materials and the stability of preparation.In addition, the spansule prepared by the present invention, auxiliary without adding other
Material, preparation process is simple, and two kinds of different mesoporous particles are absorbed by the body in stomach and small intestine respectively, hence it is evident that improves brufen and delays
Release the bioavilability of capsule.
Embodiment
Also the present invention further can be understood by embodiment, wherein the embodiment illustrates that some are prepared or user
Method.It is to be appreciated, however, that these embodiments do not limit the present invention.The change of the invention of currently known or further exploitation
Change is considered within the scope of the invention described herein and claimed below.
In following examples, used SBA-15 particle diameter is 1-2 μm, and average pore size is 8-11nm, specific surface area
600m2/g.The particle diameter of used open-cell polypropylene particle foams is 250-350 μm, and average pore size is 5-20 μm, and percent opening is
70%.
The preparation of the ibuprofen sustained release capsules of embodiment 1
1) prepared by the silica slow-releasing granules of load brufen
0.5g SBA-15 (Shanghai Zhen Zhun bio tech ltd) and 0.2g polyethylene glycol 400s are added into 50ml ethanol
Middle ultrasonic 10-15min；Then 0.5g brufens are added into dicyandiamide solution, rotary evaporation of solvent after 4h is stirred at room temperature and is obtained
Load the SBA-15 particles of brufen；0.5g hypromellose phthalates are dissolved in 50ml methanol-acetone solution (bodies
Product compares 1：1) in, then added into solution after the SBA-15 particles that 1g loads brufen, stirring 1h, rotary evaporation of solvent is obtained
It is standby that the particle obtained crushed 40 mesh sieves；
2) prepared by the perforate polypropylene foam slow-releasing granules of load brufen
By 0.4g open-cell polypropylene particle foams (being purchased from Shanghai Jun Sheng bio tech ltd) and 0.1g polyethylene glycol
400 add ultrasound 15-20min in 50ml ethanol；0.5g brufens are added into dicyandiamide solution, solvent is evaporated under reduced pressure after stirring and obtains
The open-cell polypropylene particle foams of brufen must be loaded；0.3g IV acrylic resins are dissolved in 30ml ethanol, Ran Houxiang
The open-cell polypropylene particle foams of 0.9g load brufen are added in solution, 30min is stirred, solvent is evaporated under reduced pressure, acquisition
Particle crushed 40 mesh sieves, was produced with loading loading capsule after the silica dioxide granule of brufen is well mixed.
The preparation of the ibuprofen sustained release capsules of embodiment 2
1) prepared by the silica slow-releasing granules of load brufen
By 0.5g SBA-15 (Shanghai Zhen Zhun bio tech ltd), 0.2g polyethylene glycol 400s and 30mg palmitic acid first
Ester adds ultrasound 10-15min in 50ml ethanol；Then 0.5g brufens are added into dicyandiamide solution, stirs revolved after 4h at room temperature
Turn the SBA-15 particles that evaporation solvent obtains load brufen；0.5g hypromellose phthalates are dissolved in 50ml first
Alcohol-acetone soln (volume ratio 1：1) in, then added into solution after the SBA-15 particles that 1g loads brufen, stirring 1h, rotation
Turn evaporation solvent, it is standby that the particle of acquisition crushed 40 mesh sieves；
2) prepared by the perforate polypropylene foam slow-releasing granules of load brufen
0.4g open-cell polypropylene particle foams, 0.1g polyethylene glycol 400s and 20mg methyl hexadecanoates are added into 50ml ethanol
Middle ultrasonic 15-20min；0.5g brufens are added into dicyandiamide solution, solvent is evaporated under reduced pressure after stirring and obtains load brufen
Open-cell polypropylene particle foams；0.3g IV acrylic resins are dissolved in 30ml ethanol, 0.9g is then added into solution
Load brufen open-cell polypropylene particle foams, stir 30min, solvent be evaporated under reduced pressure, the particle of acquisition crushed 40 mesh
Sieve, is produced with loading loading capsule after the silica dioxide granule of brufen is well mixed.
In Examples 1 and 2, the perforate polypropylene foam slow-releasing granules finished product density of the load brufen of preparation is in 0.7-
0.9g/cm3；Therefore it can be suspended in human gastric juice, so as to reach the purpose that stomach sustained release absorbs.
The mesoporous material brufen load capacity of embodiment 3 is investigated
20mg mesoporous materials and the polyethylene glycol and methyl hexadecanoate of various dose are taken as ultrasonic in 50ml ethanol
15min, then adds 20mg (SBA-15) and 30mg (perforate polypropylene foam) brufen respectively, and purple is passed through after stirring 6h
Determination of ibuprofen in outer spectrophotometry ethanol solution, calculates drug loading and envelop rate；Envelop rate=(add cloth Lip river
Fragrant weight-ethanol solution brufen weight)/add brufen weight；Drug loading=(add brufen weight-ethanol molten
Liquid brufen weight)/(adding brufen weight-ethanol solution brufen weight+mesoporous material weight)；Concrete outcome is as follows：
| SBA-15 | Polyethylene glycol | Methyl hexadecanoate | Envelop rate | Load capacity |
| Group 1 | - | - | 50.9% | 33.7% |
| Group 2 | 8mg | - | 78.3% | 43.9% |
| Group 3 | 8mg | 1.2mg | 91.6% | 47.8% |
| Group 4 | 12mg | - | 72.4% | 41.9% |
| Group 5 | 12mg | 2mg | 72.9% | 42.2% |
| Polypropylene foam | Polyethylene glycol | Methyl hexadecanoate | Envelop rate | Load capacity |
| Group 1 | - | - | 67.5% | 48.9% |
| Group 2 | 5mg | - | 83.9% | 55.7% |
| Group 3 | 5mg | 0.8mg | 90.4% | 57.5% |
| Group 4 | 10mg | - | 80.2% | 54.5% |
| Group 5 | 10mg | 1.2mg | 81.3% | 54.9% |
The release in vitro research of the ibuprofen sustained release capsules of embodiment 4
Ibuprofen sustained release capsules prepared by Examples 1 and 2, take two kinds of slow-releasing granules according to States Pharmacopoeia specifications, survey respectively respectively
Determine its release in simulated gastric fluid and simulated intestinal fluid, concrete outcome is as follows：
1) accumulative releasing degree in simulated gastric fluid
2) accumulative releasing degree in simulated intestinal fluid
| Type | 2h | 4h | 8h | 16h | 24h | |
| Embodiment 1 | SBA‐15 | 6.1% | 14.2% | 29.1% | 60.3% | 91.4% |
| Embodiment 2 | SBA‐15 | 6.6% | 15.9% | 33.7% | 64.8% | 95.5% |
| Comparative example 1 | SBA‐15 | 9.2% | 42.6% | 91.4% | 93.5% | 97.1% |
Comparative example 1 is the preparation method according to embodiment 2, without polyethylene glycol and palm first in mesoporous material loading process
Ester, other consumptions and proportioning be the same as Example 2
The vivo biodistribution availability research of the ibuprofen sustained release capsules of embodiment 5
Male SD rat, body weight 200g or so are taken, gavage gives cloth prepared by brufen bulk drug, Examples 1 and 2 respectively
Ibuprofen sustained release capsules content prepared by ibuprofen spansule content and comparative example, each group dosage is equal in terms of brufen
For 25mg/kg, carry out eye socket with 30min, 1h, 2h, 4h, 8h, 16h and 24h respectively and take blood, using HPLC methods to each time point
Determination of ibuprofen is detected in blood sample, calculates blood concentration, and by DAS2.0 softwares, in terms of brufen bulk drug, is calculated
The relative bioavailability of each group preparation, concrete outcome is as follows：
| AUC(0-24h) | Relative bioavailability | |
| Brufen raw material | 26.1±17.9mg/L*h | - |
| Embodiment 1 | 137.4±72.4mg/L*h | 526% |
| Embodiment 2 | 159.2±89.8mg/L*h | 610% |
| Comparative example 1 | 113.5±61.6mg/L*h | 435% |
| Comparative example 2 | 89.8±43.9mg/L*h | 344% |
The be the same as Example 4 of comparative example 1
Comparative example 2 is only comprising the SBA-15 slow-releasing granules for loading brufen in comparative example 1
The study on the stability of the ibuprofen sustained release capsules of embodiment 6
According to Chinese Pharmacopoeia two annex bulk drugs of version in 2010 and pharmaceutical preparation stability test guideline, in high temperature
(temperature is 45 DEG C ± 2 DEG C, and relative humidity is 75% ± 5%RH) carries out stability test (12 months) under super-humid conditions, passes through
Active component content in ibuprofen sustained release capsules made from HPLC detection methods measure Examples 1 and 2,0 month after being saved,
The percentage of 3 months, 6 months and the determination of ibuprofen after 12 months relative to labelled amount.
Present invention merely illustrates some claimed specific embodiments, one of them or more skill
Described technical characteristic can be combined with arbitrary one or more technical schemes in art scheme, and these are combined and obtain
Technical scheme also in the application protection domain, technical scheme is disclosed in the present invention just as obtained from these are combined
It is specific in content to record the same.
Claims (10)
1. a kind of preparation method of ibuprofen sustained release capsules, it comprises the following steps：
1) mesoporous material and polyethylene glycol are added and ultrasound is carried out in solvent；
2) brufen is added into dicyandiamide solution, stirring solvent flashing obtains the mesoporous particles of load brufen；
3) mesoporous particles are coated using organic polymer auxiliary material, the particle of acquisition pulverizes and sieves, encapsulated to produce.
2. preparation method according to claim 1, it is characterised in that the mesoporous material is selected from mesoporous silica particles
One or both of with open-cell polypropylene particle foams.
3. preparation method according to claim 2, it is characterised in that the mesoporous silica particles be selected from MCM-41,
One or more in SBA-15, HMS, MSU, SBA-3, MCM-48 and TUD-1；Preferably SBA-15, the grain of the SBA-15
Footpath is 1-2 μm, and average pore size is 8-11nm, specific surface area 600m2/g.The particle diameter of the open-cell polypropylene particle foams is 250-
350 μm, average pore size is 5-20 μm, and percent opening is 70%.
4. preparation method according to claim 1, it is characterised in that the brufen, mesoporous material and polyethylene glycol
Weight ratio is 1：0.5-5：0.1-0.5.Further, the mesoporous material is by porous of mesoporous silica particles and polypropylene
Grain composition, the weight ratio of mesoporous silica particles and the polypropylene porous particle is 1：0.2-2；Further, it is described
Brufen, mesoporous silica particles, the weight ratio of open-cell polypropylene particle foams and polyethylene glycol are 1：0.5：0.4：0.3.
5. preparation method according to claim 1, it is characterised in that the solvent is selected from methanol, ethanol, acetone and dichloro
One or more in methane.
6. preparation method according to claim 1, it is characterised in that in step 1) in, palm fibre is also added into the solvent
Palmitic acid acid methyl esters, the weight ratio of the brufen and methyl hexadecanoate is 1：0.05.
7. preparation method according to claim 1, it is characterised in that the organic polymer auxiliary material is hypromellose
Element, methylcellulose, ethyl cellulose, acrylic resin I-IV, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalic acid
One or more in ester, cellulose acetate-phthalate and styrol maleic acid copolymers.
8. the preparation method according to claim any one of 1-7, it is characterised in that the preparation of the ibuprofen sustained release capsules
Method is as follows：
1) by SBA-15 and polyethylene glycol by weight 0.5：0.2 adds ultrasound 10-15min in ethanol；
2) brufen is added into dicyandiamide solution, wherein, brufen and SBA-15 weight ratio are 1：1, stirring solvent flashing is obtained
The SBA-15 particles of brufen must be loaded；
3) hypromellose phthalate is dissolved in methanol-acetone solution (volume ratio 1：1) in, then add into solution
Enter to load the SBA-15 particles of brufen, the SBA-15 particles and hypromellose phthalate of the load brufen
Weight ratio be 2：1, solvent flashing is stirred, the particle of acquisition crushes sieving for standby；
4) by open-cell polypropylene particle foams and polyethylene glycol by weight 0.4：0.1 adds ultrasound 15-20min in ethanol；
5) brufen is added into dicyandiamide solution, wherein, the weight ratio of brufen and open-cell polypropylene particle foams is 0.5：
0.4, stirring solvent flashing obtains the open-cell polypropylene particle foams of load brufen；
6) IV acrylic resins are dissolved in ethanol, the perforate polypropylene foam of load brufen is then added into solution
Grain, the open-cell polypropylene particle foams of the load brufen and the weight ratio of IV acrylic resins are 3：1, stirring volatilization is molten
Agent, the particle of acquisition pulverizes and sieves, and the particle obtained with step 3 loads capsule after being well mixed and produced.
9. ibuprofen sustained release capsules prepared by a kind of any one of claim 1-8 preparation methods.
10. application of the ibuprofen sustained release capsules described in claim 9 in medicine in terms of preparing treatment inflammation or pain disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710403211.3A CN107184565B (en) | 2017-06-01 | 2017-06-01 | A kind of preparation method of ibuprofen sustained release capsules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710403211.3A CN107184565B (en) | 2017-06-01 | 2017-06-01 | A kind of preparation method of ibuprofen sustained release capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107184565A true CN107184565A (en) | 2017-09-22 |
| CN107184565B CN107184565B (en) | 2018-04-03 |
Family
ID=59876343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710403211.3A Active CN107184565B (en) | 2017-06-01 | 2017-06-01 | A kind of preparation method of ibuprofen sustained release capsules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107184565B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992706A (en) * | 2018-08-08 | 2018-12-14 | 上海应用技术大学 | A kind of antibiotic continues acrylic resin bone cement efficiently discharged and preparation method thereof |
| CN109966268A (en) * | 2019-04-04 | 2019-07-05 | 吉林市吴太感康药业有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN113768899A (en) * | 2021-09-29 | 2021-12-10 | 广东彼迪药业有限公司 | Colloidal bismuth pectin capsule and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1530138A (en) * | 2003-03-13 | 2004-09-22 | �����ɷ� | Stabilized medicine preparation form with by porous kietyoite covering flavour |
| CN101909601A (en) * | 2008-01-18 | 2010-12-08 | 陶氏环球技术公司 | Use methoxy poly (ethylene glycol) to strengthen the method for the water solubility of hardly soluble active substances |
| CN102448448A (en) * | 2009-05-29 | 2012-05-09 | 弗拉梅技术公司 | Controlled-release floating pharmaceutical compositions |
| CN103099789A (en) * | 2013-02-21 | 2013-05-15 | 河北维尔康制药有限公司 | Preparation method of vitamin C granules |
| CN103565765A (en) * | 2012-07-30 | 2014-02-12 | 南京亿华药业有限公司 | Preparation of ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug |
| CN104415340A (en) * | 2013-08-23 | 2015-03-18 | 中国科学院大连化学物理研究所 | Solid drug preparation and preparing method thereof |
-
2017
- 2017-06-01 CN CN201710403211.3A patent/CN107184565B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1530138A (en) * | 2003-03-13 | 2004-09-22 | �����ɷ� | Stabilized medicine preparation form with by porous kietyoite covering flavour |
| CN101909601A (en) * | 2008-01-18 | 2010-12-08 | 陶氏环球技术公司 | Use methoxy poly (ethylene glycol) to strengthen the method for the water solubility of hardly soluble active substances |
| CN102448448A (en) * | 2009-05-29 | 2012-05-09 | 弗拉梅技术公司 | Controlled-release floating pharmaceutical compositions |
| CN103565765A (en) * | 2012-07-30 | 2014-02-12 | 南京亿华药业有限公司 | Preparation of ibuprofen orally-disintegrating pellet coated by compound essence powder and capable of hierarchically releasing drug |
| CN103099789A (en) * | 2013-02-21 | 2013-05-15 | 河北维尔康制药有限公司 | Preparation method of vitamin C granules |
| CN104415340A (en) * | 2013-08-23 | 2015-03-18 | 中国科学院大连化学物理研究所 | Solid drug preparation and preparing method thereof |
Non-Patent Citations (5)
| Title |
|---|
| SW SONG等人: ""Functionalized SBA-15 Materials as Carriers for Controlled Drug Delivery:Influence of Surface Properties on Matrix-Drug Interactions"", 《LANGMUIR THE ACS JOURNAL OF SURFACES & COLLOIDS》 * |
| WUJUN XU等人: ""pH-Controlled drug release from mesoporous silica tablets coated with hydroxypropyl methylcellulose phthalate"", 《MATERIALS RESEARCH BULLETIN》 * |
| 倪敏等人: ""布洛芬/SBA-15 纳米缓控释药物的超临界制备及其释放特性研究"", 《第九届全国超临界流体技术学术及应用研讨会论文集》 * |
| 徐武军: ""基于HPMCP包覆介孔SBA-15的pH敏感药物缓释系统"", 《化学学报》 * |
| 赵飞船: ""布洛芬在中孔分子筛上的负载与缓释研究"", 《中国知网系列数据库（CNKI）》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992706A (en) * | 2018-08-08 | 2018-12-14 | 上海应用技术大学 | A kind of antibiotic continues acrylic resin bone cement efficiently discharged and preparation method thereof |
| CN109966268A (en) * | 2019-04-04 | 2019-07-05 | 吉林市吴太感康药业有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN113768899A (en) * | 2021-09-29 | 2021-12-10 | 广东彼迪药业有限公司 | Colloidal bismuth pectin capsule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107184565B (en) | 2018-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101583620B (en) | Ganaxolone formulations and preparation and application thereof | |
| JP4969104B2 (en) | Porous cellulose aggregate and molded body composition thereof | |
| CN107184565B (en) | A kind of preparation method of ibuprofen sustained release capsules | |
| JPWO2006115198A1 (en) | Porous cellulose aggregate and molded body composition thereof | |
| CN103550158B (en) | Emodin solid dispersion, drug-containing pellet core, colonic targeted micropill, and applications of three | |
| CN103610649A (en) | Medicament microsphere and preparation method thereof | |
| CN103784396B (en) | Ibuprofen oral micropill xerogel and preparation method thereof | |
| CN113842370B (en) | Abidol hydrochloride tablet and preparation method thereof | |
| CN106983734B (en) | A kind of ibuprofen sustained release capsules and preparation method thereof | |
| Nguyen et al. | Rapid Indomethacin Release from Porous Pectin Particles as a Colon-Targeted Drug Delivery System | |
| CN1771913B (en) | Emulifying solvent diffusing process for preparing taste masked micro ball | |
| Zhang et al. | Development of protocatechualdehyde proliposomes-based sustained-release pellets with improved bioavailability and desired pharmacokinetic behavior for angina chronotherapy | |
| CN103860464B (en) | A kind of Claritin slow-release suspension and preparation method thereof | |
| CN108042495B (en) | A kind of Glipizide lipid nano particle solid pharmaceutical preparation | |
| CN100562322C (en) | Colon targeting preparation of a kind of 5-aminosalicylic acid and preparation method thereof | |
| CN105732517A (en) | Medicine preparation containing 5-fluorouracil drug eutectic with nicotinamide as precursor and preparation method of medicine preparation | |
| Mehta et al. | Solvent evaporation technique: An innovative approach to increase gastric retention | |
| Gupta et al. | Fabrication and evaluation of fluvastatin sodium loaded sustained release microspheres using polymer blends | |
| CN104288107B (en) | Sustained-release floating micropill, pharmaceutical composition containing the pellet and preparation method thereof | |
| Kouchak et al. | Preparation and in vitro evaluation of a microballoon delivery system for theophylline | |
| CN107456444B (en) | Mosapride sustained-release dry suspension and preparation method thereof | |
| CN102631324A (en) | Nimesulide self-emulsification particle and preparation method thereof | |
| WO2016119114A1 (en) | Puerarin nanocrystalline capsule and preparation method therefor | |
| CN101647782A (en) | Vinpocetine oral administration self-microemulsifying pellet as well as preparation method and application thereof | |
| CN104027316B (en) | A glimepiride tablet and a preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |